99 related articles for article (PubMed ID: 29947237)
1. Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.
Akin DF; Oner DA; Kurekci E; Akar N
Bratisl Lek Listy; 2018; 119(6):366-372. PubMed ID: 29947237
[TBL] [Abstract][Full Text] [Related]
2. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
5. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
6. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
7. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
Zhang Q; Bai S; Vance GH
Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693
[TBL] [Abstract][Full Text] [Related]
9. Molecular evaluation of CEBPA gene mutation in normal karyotype acute myeloid leukemia: a comparison of two methods and report of novel CEBPA mutations from Indian acute myeloid leukemia patients.
Ahmad F; Rajput S; Mandava S; Das BR
Genet Test Mol Biomarkers; 2012 Jul; 16(7):707-15. PubMed ID: 22731647
[TBL] [Abstract][Full Text] [Related]
10. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
[TBL] [Abstract][Full Text] [Related]
11. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
[TBL] [Abstract][Full Text] [Related]
12. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
[TBL] [Abstract][Full Text] [Related]
13. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
14. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
15. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
[TBL] [Abstract][Full Text] [Related]
16. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
[TBL] [Abstract][Full Text] [Related]
17. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
He J; Liu J; Shen H; Wang Z; Cao L; Wu P; Chao H; Lu X; Jia Z; Chen M; Cai X
Int J Hematol; 2022 Jul; 116(1):71-80. PubMed ID: 35314954
[TBL] [Abstract][Full Text] [Related]
18. Decision Analysis of Postremission Therapy in Cytogenetically Intermediate-Risk Acute Myeloid Leukemia: The Impact of FLT3 Internal Tandem Duplication, Nucleophosmin, and CCAAT/Enhancer Binding Protein Alpha.
Kurosawa S; Yamaguchi H; Yamaguchi T; Fukunaga K; Yui S; Wakita S; Kanamori H; Usuki K; Uoshima N; Yanada M; Shono K; Ueki T; Mizuno I; Yano S; Takeuchi J; Kanda J; Okamura H; Inamoto Y; Inokuchi K; Fukuda T
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1125-1132. PubMed ID: 27040395
[TBL] [Abstract][Full Text] [Related]
19. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
Ahn SY; Kim T; Kim M; Song GY; Jung SH; Yang DH; Lee JJ; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim HJ; Ahn JS; Kim DDH
Cancer Res Treat; 2023 Jul; 55(3):1011-1022. PubMed ID: 36701843
[TBL] [Abstract][Full Text] [Related]
20. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.
Dunlap J; Beadling C; Warrick A; Neff T; Fleming WH; Loriaux M; Heinrich MC; Kovacsovics T; Kelemen K; Leeborg N; Gatter K; Braziel RM; Press R; Corless CL; Fan G
Hum Pathol; 2012 Dec; 43(12):2167-76. PubMed ID: 22658276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
